Search results for "Adverse effect"

showing 10 items of 1065 documents

Difficult tracheal intubation in neonates and infants. NEonate and Children audiT of Anaesthesia pRactice IN Europe (NECTARINE)

2021

Background: Neonates and infants are susceptible to hypoxaemia in the perioperative period. The aim of this study was to analyse interventions related to anaesthesia tracheal intubations in this European cohort and identify their clinical consequences. Methods: We performed a secondary analysis of tracheal intubations of the European multicentre observational trial (NEonate and Children audiT of Anaesthesia pRactice IN Europe [NECTARINE]) in neonates and small infants with difficult tracheal intubation. The primary endpoint was the incidence of difficult intubation and the related complications. The secondary endpoints were the risk factors for severe hypoxaemia attributed to difficult airw…

MaleTime Factorspaediatricmedicine.medical_treatmentmorbiditySeverity of Illness Index0302 clinical medicine030202 anesthesiologyRisk FactorsClinical endpointAnesthesiaProspective Studies610 Medicine & healthHypoxiapaediatric.Medical Auditmedicine.diagnostic_testddc:617infantsIncidence (epidemiology)IncidenceAge Factorsanaesthesiarespiratory systemEuropeTreatment OutcomeAnesthesiaCohortFemalemedicine.symptomBradycardiaLaryngoscopy610 Medicine & healthAnesthesia/adverse effects/mortalityRisk AssessmentEurope/epidemiology03 medical and health sciencesLaryngoscopy/adverse effects/mortalityHypoxia/diagnosis/epidemiology/mortalitymedicineIntubation IntratrachealHumansdifficult intubationLaryngoscopybusiness.industryTracheal intubationInfant NewbornInfantPerioperativeNewborn3126 Surgery anesthesiology intensive care radiologymortalityneonatesClinical trialIntratrachealAnesthesiology and Pain MedicineairwayIntubation Intratracheal/adverse effects/mortalityneonateIntubationbusinessairwaysBritish Journal of Anaesthesia
researchProduct

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.

2010

The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain.This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 µg/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated.Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a me…

MaleTransdermal patchCancer pain; Opioids; Trandermal fentanyl; Aged; Analgesia; Analgesics Opioid; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms; Pain; Palliative Care; Transdermal Patch; Medicine (all)medicine.medical_treatmentPainTransdermal PatchOpioidFentanylDose-Response RelationshipNeoplasmsmedicineHumansCancer painAdverse effectNeoadjuvant therapyTransdermalAgedAnalgesicsDose-Response Relationship Drugbusiness.industryMedicine (all)Palliative CareGeneral MedicineMiddle AgedNeoadjuvant TherapyOpioidsClinical trialAnalgesics OpioidFentanylTolerabilityTrandermal fentanylAnesthesiaFemaleDrugAnalgesiaCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano.

2012

Background The Bolivian northern Altiplano is characterized by a high prevalence of Fasciola hepatica infection. In order to assess the feasibility, safety and efficacy of large-scale administration of triclabendazole as an appropriate public health measure to control morbidity associated with fascioliasis, a pilot intervention was implemented in 2008. Materials and Methods Schoolchildren from an endemic community were screened for fascioliasis and treated with a single administration of triclabendazole (10 mg/kg). Interviews to assess the occurrence of adverse events were conducted on treatment day, one week later, and one month after treatment. Further parasitological screenings were perf…

MaleVeterinary medicineEndemic DiseasesNon-Clinical Medicinemedicine.medical_treatmentRC955-962Arctic medicine. Tropical medicineMedicineChildAnthelminticsbiologyTreatment OutcomeInfectious DiseasesTriclabendazoleChild PreschoolMedicineFemalePublic HealthPublic aspects of medicineRA1-1270After treatmentResearch Articlemedicine.drugSingle administrationBoliviaFascioliasismedicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse ReactionsChemopreventionInterviews as TopicInternal medicineparasitic diseasesAnimalsHumansFasciola hepaticaAdverse effectTriclabendazoleTreatment GuidelinesChemotherapyHealth Care Policybusiness.industryPublic healthPublic Health Environmental and Occupational HealthDrug PolicyFasciola hepaticabiology.organism_classificationParasitologyBenzimidazolesPreventive MedicinebusinessPLoS Neglected Tropical Diseases
researchProduct

Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?

2006

Abstract Background While opioids in increasing doses may produce adverse effects, the same adverse effects may be associated with poor pain control. Moreover, in the clinical setting symptomatic treatment and illness may balance the outcome of opioid titration. Some adverse effects may tend to disappear continuing the treatment in a long-term period. Aims The aim of this study was to monitor the effects of a rapid opioid titration combined with symptomatic treatment in patients with poor relief and to monitor these changes in the following period of 20 days. Methods A consecutive sample of 35 patients admitted to an acute Pain Relief and Palliative Care Unit were titrated with opioids, acc…

MaleWeaknessPalliative careConstipationNauseaOpioid-induced symptoms; pain relief; advanced cancer patients; longitudinal prospective studymedia_common.quotation_subjectPainpain reliefadvanced cancer patientlongitudinal prospective studyNeoplasmsmedicineHumansLongitudinal StudiesProspective StudiesAdverse effectmedia_commonbusiness.industryPalliative CareAppetiteMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidPatient SatisfactionAnesthesiaEmergency MedicineVomitingFemalemedicine.symptomCancer painbusinessOpioid-induced symptommedicine.drug
researchProduct

The use of corticosteroids in home palliative care

2001

Evidence for the effectiveness of corticosteroids in palliative care is anecdotal, and more information is required. From January to December 1999 a total of 376 consecutive patients admitted to a home palliative care program were longitudinally surveyed. Patients who started a corticosteroid treatment after admission on the basis of common indications prescribed by their home care physicians were selected. Fifty patients were enrolled in the study. Dexametha-sone, in doses ranging from 4 to 16 mg, was the drug of choice. Corticosteroids were found to be effective in anorexia, weakness, headache, and nausea and vomiting. The reduction of symptom intensity was achieved in less than 3 days on…

MaleWeaknessPediatricsmedicine.medical_specialtyPalliative careNauseaLongitudinal epedemiological studyAnorexiaHome palliative careDexamethasoneStatistics NonparametricmedicineHumansCorticosteroidLongitudinal StudiesAdverse effectIntensive care medicineGlucocorticoidsNursing (all)2901 Nursing (miscellaneous)AgedAged 80 and overbusiness.industryPalliative CareTherapeutic effectMiddle Agedmedicine.diseaseHome Care ServicesBowel obstructionItalyOncologyVomitingFemalemedicine.symptombusiness
researchProduct

Arterial Stiffness and Its Relationship to Cardiorespiratory Fitness in Children and Young Adults with a Fontan Circulation

2019

There are no previous studies on arterial stiffness and its associations with cardiorespiratory fitness in young Fontan patients. Therefore, we examined the arterial stiffness and its relationship to cardiorespiratory fitness in children and young adults with a Fontan circulation. Altogether, 17 Fontan patients and 26 healthy controls (16 females and 27 males aged 8–40 years) participated in this cross-sectional study. The cardiorespiratory fitness was assessed by cardiopulmonary exercise testing on a cycle ergometer and was defined as the standard deviation scores (SDS) of peak oxygen uptake per body mass (VO2peak/kg) based on the national reference values and assessed with cardiopulmonary…

MaleYouthsynnynnäiset sydänviatAugmentation Index030204 cardiovascular system & hematologyFontan Procedureaugmentation indexPediatricsuniventricular heart0302 clinical medicinenuoretFontan circulationChildAorta/physiopathologyPulse wave velocityAortaCardiorespiratory Fitness/physiologyHeart Defectseducation.field_of_studycardiorespiratory fitnessExercise Test/methodsVO2 maxMiddle AgedPerinatologyArterial stiffnessand Child HealthCongenital/physiopathologyfyysinen kuntoarterial stiffnessCardiorespiratory FitnessCardiologyOriginal ArticleFemaleCardiology and Cardiovascular MedicineHeart Defects CongenitalAdultmedicine.medical_specialtyAdolescentpulse wave velocityPopulationVascular Stiffness/physiologylapset (ikäryhmät)Pulse Wave AnalysisYoung Adult03 medical and health sciencesVascular StiffnessOscillometry030225 pediatricsInternal medicineJournal ArticlemedicineHumansPediatrics Perinatology and Child Healtheducationnuoret aikuisetbusiness.industryUniventricular heartFontan Procedure/adverse effectsCardiorespiratory fitnessHeart Defects Congenital/physiopathologyAortic Augmentation Indexmedicine.diseaseConfidence intervalPulse wave velocityCross-Sectional StudiesPulse Wave Analysis/methodsPediatrics Perinatology and Child HealthExercise TestArterial stiffnessnuoruusfontan circulationbusinessBody mass indexhuman activities
researchProduct

A Double-Blind Randomized Controlled Trial (RCT) of Titanium-13Zirconium versus Titanium Grade IV Small-Diameter Bone Level Implants in Edentulous Ma…

2012

Background: The use of endosseous dental implants has become common practice for the rehabilitation of edentulous patients, and a two-implant overdenture has been recommended as the standard of care. The use of small-diameter implants may extend treatment options and reduce the necessity for bone augmentation. However, the mechanical strength of titanium is limited, so titanium alloys with greater tensile and fatigue strength may be preferable. Purpose: This randomized, controlled, double-blind, multicenter study investigated in a split-mouth model whether small-diameter implants made from Titanium-13Zirconium alloy (TiZr, Roxolid™) perform at least as well as Titanium Grade IV implants. Me…

MaleZIRCONIUM ALLOYSDentistrychemistry.chemical_elementMandiblelaw.inventionDouble-Blind MethodRandomized controlled triallawalloyDental Prosthesis DesignHumansJaw EdentulousMedicinebone level implantBone leveledentulous mandibleORAL-HEALTHAdverse effectGeneral DentistryAgedAged 80 and overTitaniumSUPPORTED OVERDENTURESbusiness.industrySPLIT-MOUTHDental Implantation EndosseousTitanium alloySoft tissueSUCCESSOSSEOINTEGRATED IMPLANTSMiddle Agedddc:617.6Treatment OutcomeDental Prosthesis Designchemistryddc:618.97DENTAL IMPLANTSFemaleImplantZirconiumOral Surgerydouble-blindLocatorbusinessFOLLOW-UPITI IMPLANTSRCTTitaniumClinical implant dentistry and related research
researchProduct

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

2013

International audience; Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previously untreated adults with chronic hepatitis C genotype 1. We evaluate the relationship of incident anemia with triple therapy. A total of 1,097 patients received a 4-week lead-in of PegIFN/RBV followed by: (1) placebo plus PegIFN/RBV for 44 weeks (PR48); (2) BOC plus PegIFN/RBV using response-guided therapy (BOC/RGT); and (3) BOC plus PegIFN/RBV for 44 weeks (BOC/PR48). The management of anemia (hemoglobin [Hb]<10 g/dL) included RBV dose reduction and/or erythropoietin (EPO) use. A total of 1,080…

Male[SDV]Life Sciences [q-bio]MedizinGastroenterologyPolyethylene GlycolsPlaceboschemistry.chemical_compoundHemoglobins0302 clinical medicinehemic and lymphatic diseasesMedicine030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaInterferon-alpha; Serine Proteinase Inhibitors; Proline; Recombinant Proteins; Hematinics; Humans; Ribavirin; Anemia; Antiviral Agents; Drug Therapy Combination; Erythropoietin; Hemoglobins; Adult; Treatment Outcome; Placebos; Polyethylene Glycols; Hepatitis C Chronic; Female; MaleAnemiaHepatitis CHepatitis CRecombinant Proteins3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeCombinationPeginterferon alfa-2b030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsProlineAnemiaInterferon alpha-2PlaceboAntiviral Agentsprotease inhibitor03 medical and health sciencesDrug TherapyInternal medicineBoceprevirRibavirinHumansAdverse effectErythropoietinHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgerychemistryErythropoietinHematinicsbusiness
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

OnabotulinumtoxinA: how deep will it go?

2014

First-line treatment of overactive bladder syndrome (OAB) is based on conservative measures and oral medication such asmuscarinic receptor antagonists and, more recently, b3-adrenoceptor agonists.While this provides effective symptom relief for many patients, for others it has insufficient efficacy and/or intolerable side effects. The potent neurotoxin onabotulinumtoxinA (BoNT-A) has shown efficacy in placebo-controlled trials in patients with neurogenic voiding dysfunction or OAB [1], largely including patients exhibiting an insufficient treatment response to muscarinic antagonists. Although the role of a strong placebo component in the beneficial effects of oral treatment is well known, a…

Malebusiness.industryUrinary Bladder OveractiveUrologyIncidence (epidemiology)Urinary systemAcetylcholine Release InhibitorsPlaceboRefractoryQuality of lifeOral administrationAnesthesiaMedicineHumansFemaleBotulinum Toxins Type AAdverse effectLead (electronics)businessEuropean urology
researchProduct